Navigation Links
More surgery in early-stage laryngeal cancer treatment; more chemoradiation for advanced-stage
Date:10/17/2011

CHICAGO The use of surgery to treat early-stage laryngeal cancer (cancer of the voice box) is increasing in the United States, and chemotherapy in combination with radiation therapy is being used increasingly to treat patients in an advanced stage of the disease, according to a report in the October issue of Archives of Otolaryngology Head & Neck Surgery, one of the JAMA/Archives journals.

Cancer of the larynx, or voice box, was diagnosed in nearly 13,000 people in the U.S. in 2010, and 3,660 were projected to die from the disease, according to background information in the article. Early-stage laryngeal cancer has traditionally been treated with radiation therapy or surgical resection (removal of part of the larynx) with comparable successful outcomes.

Amy Y. Chen, M.D., M.P.H., and colleagues at Emory University and the American Cancer Society, Atlanta, conducted a study to examine trends and four-year survival rates of surgical and non-surgical treatment for laryngeal cancer. They analyzed data on 131,694 laryngeal cancer cases diagnosed from 1985 to 2007, identified from the National Cancer Database. The primary treatment information included radiation therapy (RT), chemoradiation (CRT, chemotherapy in combination with radiation therapy), and curative intent surgery.

The authors found that surgical resection of early-stage laryngeal cancer increased over the years, with a corresponding decrease in radiation.

"Among patients with early-stage cancer, the proportion receiving primary surgery increased (from 20 percent in 1985 to 33 percent in 2007), whereas the use of RT decreased from 64 percent to 52 percent," they report. "The four-year survival rate for patients with early-stage laryngeal cancer treated with surgery was higher than the rate for those treated with RT (79 percent vs. 71 percent)."

"Among patients with advanced-stage cancer, the use of CRT increased from less than 7 percent to 45 percent, whereas the use of total laryngectomy [surgical removal of the voice box] decreased from 42 percent to 32 percent," they continue.

Advanced-stage patients who had total laryngectomy had a four-year survival rate of 51 percent. The survival rate for patients treated with CRT was 48 percent, and for those treated with RT the survival rate was 38 percent.

Patients who lived in areas with higher socioeconomic status zip codes and who had private insurance were more likely to be treated with surgery for early-stage laryngeal cancer, and to receive CRT for advanced-stage cancer. Early-stage patients who were not African American, and who were treated at academic facilities, were more likely to receive surgery. Younger patients with advanced-stage cancer were more likely to be treated with CRT.

"Not only were clinical factors associated with type of treatment, but select sociodemographic elements were also associated with treatment," the authors conclude. "Further investigation as to the decision-making process of patients with different sociodemographic backgrounds will assist in mitigating the differences in survival for this group of patients."


'/>"/>
Contact: Kathi Baker
kobaker@emory.edu
404-727-9371
JAMA and Archives Journals
Source:Eurekalert

Related medicine news :

1. Repeated Weight-Loss Surgery Carries Added Risks
2. The New Liposuction Technique Means No Surgery or Suction
3. Research validates surgery alone offers reasonable overall survival for stage I SCLC
4. "New Cosmetic Surgery" Journalism Prize
5. Abington Memorial Hospital Welcomes Vakil to Orthopaedic Surgery Division
6. Drug for advanced kidney cancer shrinks tumors prior to surgery
7. Abington Memorial Hospital Earns Two Designations: Blue Distinction Center for Spine Surgery(SM) and Blue Distinction Center for Knee and Hip Replacement(SM)
8. New endoscopic treatment may spare Barretts esophagus patients from surgery
9. Pittsburgh Neurosurgeons Explore Use of Drug that Illuminates Brain Tumor Cells To Guide Surgery
10. Surgery Alone May Thwart Stage 1 Lung Cancer
11. Comparison shows robot-assisted option offers advantages for kidney surgery
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/3/2016)... ... May 03, 2016 , ... LunchSkins is changing the ... replace billions of single-use, throw away plastic baggies. The mission-driven bags give back to ... life. , “The LunchSkins mission is all about reducing global plastic waste ...
(Date:5/3/2016)... (PRWEB) , ... May 03, ... ... Carnival Cruise Lines premiered the state-of-the-art Carnival Vista – the line’s largest ... ship, The Cruise Web has created an infographic spotlighting the Carnival ...
(Date:5/2/2016)... ... May 02, 2016 , ... It has just been ... keynote speaker for five events throughout the month of May. , Uldrich is the ... national news outlets. He also frequently appears on the Science Channel’s FutureScape and Discovery ...
(Date:5/2/2016)... Dallas, Texas (PRWEB) , ... May 02, 2016 ... ... Volume 3, Issue 1 of Patient Experience Journal (PXJ), an international, open ... patient experience. With almost half the issue representing international (non-US) based authors, the ...
(Date:5/2/2016)... ... May 02, 2016 , ... Beanfields, PBC, ... by partnering with college students at University of Colorado in Boulder to create ... advertising campaigns class in the School of Journalism, who selected Beanfields as the ...
Breaking Medicine News(10 mins):
(Date:4/28/2016)... 28, 2016 ... Phillips und Stephen Schmidt ... ArisGlobal®, ein führender Anbieter cloudbasierter Softwarelösungen ... bekannt, dass neue Führungskräfte zum Team Sicherheit ... die vielfältige Erfahrungen mitbringen.  Dies wird die ...
(Date:4/28/2016)... TOKYO , April 28, 2016 ... and Ste phen ... ArisGlobal®, a leading provider of cloud-based software solutions for ... and Pharmacovigilance team to bring a wealth of insight to a ... unparalleled pharmacovigilance knowledge. George Phillips joined ArisGlobal ...
(Date:4/28/2016)... -- TapImmune,Inc. (TPIV), a clinical-stage immune-oncology ... immunotherapeutics and vaccines for the treatment of cancer & metastatic ... Annual Growth Capital Expo to be held on May ... Palace in Las Vegas, Nevada.  The Company presentation will ... by Dr. John N. Bonfiglio a TapImmune ...
Breaking Medicine Technology: